Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to ...
At World Sleep 2025, Robson Capasso, MD, of Stanford University in California, challenged the field's reliance on the apnea-hypopnea index (AHI) as the primary measure of treatment success in ...
Two randomized controlled trials show reduction in AHI; significant improvements seen in all secondary end points. (HealthDay News) — Tirzepatide reduces the apnea-hypopnea index (AHI) among ...
Early management of obstructive sleep apnea in patients with IPF could slow disease progression and improve outcomes.
Sleep apnea is a debilitating disease that many sufferers don’t even realize they have. Those afflicted with the condition ...
Mirroring results reported in a phase IIb study, Apnimed Inc.’s first of two pivotal trials testing AD-109 as an oral therapy in obstructive sleep apnea hit primary and secondary endpoints. Should ...
Middle-aged adults with comorbid insomnia and sleep apnea faced significantly elevated odds for uncontrolled hypertension vs. adults without these conditions, according to results published in Annals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results